Perindopril (erbumine)

Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure^[1][2][3][4]. In Vitro:Perindopril erbumine (1 μM, 24 h) ameliorats gliosis and blunts decrease induced by LPS (HY-D1056) in AT2R expression in Rat astrocytoma cell line (C6) and murine microglial cell line (BV2)^[1].
Perindopril erbumine (1 μM, 24 h) prevents IκBα degradation, NF-кB nuclear translocation and STAT3 activation induced by LPS (HY-D1056) in C6 and BV2^[1].
Perindopril erbumine (1 μM, 24 h) ameliorats the imbalance in the release of inflammatory cytokine and blunts the aberrant ROS production and the nitrite release induced by LPS (HY-D1056) in C6 and BV2^[1]. In Vivo:Perindopril erbumine (0.1 mg/kg, Oral gavage, once a day for five consecutive days) prevents LPS-induced neuroinflammation in rats^[1].
Perindopril erbumine (0.42 mg/kg, Oral, once a day for 4 weeks) with Huangqi-Danshen decoction (HDD) (4.7 g/kg, Oral, once a day for 4 weeks) attenuates adenine(HY-B0152)-induced Chronic kidney disease (CKD) in rats^[2].
Perindopril erbumine (0.4-1.5 mg/kg, Oral, once a day for 4-24 weeks) has a persistent effect on blood pressure in spontaneously hypertensive rats (SHR)^[4].